These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29035723)

  • 1. Raloxifene reduces the risk of local alveolar bone destruction in a mouse model of periodontitis combined with systemic postmenopausal osteoporosis.
    Ichimaru R; Tominari T; Yoshinouchi S; Matsumoto C; Watanabe K; Hirata M; Numabe Y; Murphy G; Nagase H; Miyaura C; Inada M
    Arch Oral Biol; 2018 Jan; 85():98-103. PubMed ID: 29035723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
    Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
    Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between postmenopausal osteoporosis and inflammatory periodontitis regarding bone loss in experimental models.
    Kobayashi M; Matsumoto C; Hirata M; Tominari T; Inada M; Miyaura C
    Exp Anim; 2012; 61(2):183-7. PubMed ID: 22531735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
    Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
    Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis.
    Jochems C; Islander U; Kallkopf A; Lagerquist M; Ohlsson C; Carlsten H
    Arthritis Rheum; 2007 Oct; 56(10):3261-70. PubMed ID: 17907171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice.
    Onoe Y; Miyaura C; Ito M; Ohta H; Nozawa S; Suda T
    J Bone Miner Res; 2000 Mar; 15(3):541-9. PubMed ID: 10750569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
    Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
    J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis.
    Beekman KM; Veldhuis-Vlug AG; den Heijer M; Maas M; Oleksik AM; Tanck MW; Ott SM; van 't Hof RJ; Lips P; Bisschop PH; Bravenboer N
    Bone; 2019 Jan; 118():62-68. PubMed ID: 29032175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oestrogen deficiency on the alveolar bone of rats with experimental periodontitis.
    Xu XC; Chen H; Zhang X; Zhai ZJ; Liu XQ; Zheng XY; Zhang J; Qin A; Lu EY
    Mol Med Rep; 2015 Sep; 12(3):3494-3502. PubMed ID: 26035209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New management options for osteoporosis with emphasis on SERMs.
    McClung MR
    Climacteric; 2015; 18 Suppl 2():56-61. PubMed ID: 26503459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.
    Genant HK; Lang T; Fuerst T; Pinette KV; Zhou C; Thiebaud D; Diez-Perez A
    Bone; 2004 Nov; 35(5):1164-8. PubMed ID: 15542042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-mouse RANKL Antibodies Inhibit Alveolar Bone Destruction in Periodontitis Model Mice.
    Kuritani M; Sakai N; Karakawa A; Isawa M; Chatani M; Negishi-Koga T; Funatsu T; Takami M
    Biol Pharm Bull; 2018; 41(4):637-643. PubMed ID: 29607937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
    Chmel R; Rob L; Strnad P
    Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.